A Study to Assess the Role of Biomarkers in Risk Stratification in Adults with Congenital Heart Disease

Overview

About this study

The purporse of this study is to determine if biomarker assay obtained at baseline can predict future risk of cardiovascular adverse events, and to  determine if temporal changes in biomarker levels can provide a better risk prediction compared to biomarker assay obtained at baseline.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Adult patients (age >18 years)
  • Adult patients with diagnosis of Tetralogy of Fallot (TOF), Pulmonary Atresia, Valvular Pulmonic Stenosis, Coarctation of Aorta, Ebstein Anomaly, Congenitally Corrected TGA (L-TGA) and history of Fontan palliation will be eligible for this study.

Exclusion Criteria: 

  • Patients without research authorization.

 

 

 

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alexander Egbe, M.B.B.S., M.P.H.

Open for enrollment

Contact information:

Halley Davison

(507)422-6246

davison.halley@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20463718

Mayo Clinic Footer